Results 251 to 260 of about 1,142,872 (298)
Remission induction in rheumatoid arthritis.
openaire +1 more source
Human Monocytic Models Reveal Genotype‐Dependent Inflammatory Programs in VEXAS Syndrome
Objective VEXAS syndrome is a severe X‐linked autoinflammatory disorder caused by somatic mutations in ubiquitin‐like modifier activating enzyme 1 (UBA1), with clinical outcomes that vary by UBA1 genotype. We aimed to elucidate genotype‐specific inflammatory programs and identify potential therapeutic targets.
Kana Higashitani +10 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Induction of Remission in Hepatocellular Carcinoma With Doxorubicin.
Lancet, The, 1978Doxorubicin (60 mg/m2 at 3-weekly intervals to a maximum total of 550 mg/m2) induced clinical remission in 14 (32%) of 44 patients with hepatocellular carcinoma. In 3 of those who responded, hepatic arteriography showed clearing of the previously extensive tumour circulation, and in a 4th there was disappearance of the tumour on serial ultrasound ...
I M Murray-Lyon +2 more
exaly +3 more sources
Induction of Durable Remission in Ocular Inflammatory Diseases
Purpose To describe a paradigm of care for patients with ocular inflammatory diseases aimed at induction of durable remission. Methods Retrospective cohort study.
R A, Cervantes-Castaneda +4 more
openaire +3 more sources
The face of remission induction
British Journal of Haematology, 2019SummaryAcute myeloid leukaemia (AML) is a heterogeneous disease in which prognosis is determined by cytogenetic and molecular aberrations as well as patient‐related factors, including age, prior haematologic disorders, and comorbidities. Despite the diverse disease biology, the standard of care for remission induction therapy has changed very little ...
Shilpa Paul +2 more
openaire +2 more sources
Most patients with acute myeloid leukemia (AML) receive intensive induction chemotherapy toward obtaining a complete remission. In this study, we evaluated whether the time from induction chemotherapy to complete remission in patients with AML affects ...
Rafiye Çiftçiler +2 more
exaly +2 more sources
Natalizumab for induction of remission in Crohn's disease
Cochrane Database of Systematic Reviews, 2006The pathogenesis of Crohn's disease involves migration of leukocytes into gut tissue and subsequent inflammation. Natalizumab (Tysabri(R), Elan Pharmaceuticals and Biogen Idec) a recombinant humanized IgG4 monoclonal antibody that blocks adhesion and subsequent migration of leukocytes into the gut by binding the alpha4 integrin is a member of a new ...
J K, Macdonald, J W D, McDonald
openaire +3 more sources
Budesonide for induction of remission in Crohn's disease
Cochrane Database of Systematic Reviews, 2015Corticosteroids are commonly used for the induction of remission in Crohn's disease. However, traditional corticosteroids can cause significant adverse events. Budesonide is an alternative glucocorticoid with limited systemic bioavailability.The primary objective was to evaluate the efficacy and safety of oral budesonide for the induction of remission ...
Ali, Rezaie +7 more
openaire +2 more sources
Methotrexate for induction of remission in ulcerative colitis
2007Ulcerative colitis is a chronic inflammatory bowel disease. Corticosteroids and 5-aminosalicylates are the most commonly used therapies. However, many patients require immunosuppressive therapy when their disease becomes steroid-refractory or dependent.
N, Chande +2 more
openaire +2 more sources

